Overview

Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation

Status:
Unknown status
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
This is a study of HMB plus amino acids in older men with prostate cancer starting androgen deprivation therapy (ADT). The investigators hypothesize that the use of this nutritional supplementation will decrease the loss of muscle mass and strength that occurs when men start ADT.
Phase:
Phase 2
Details
Lead Sponsor:
Medical College of Wisconsin
Treatments:
Androgens
Ascorbic Acid
Estrogens, Conjugated (USP)
Methyltestosterone